Liposomal delivery systems showed 33.1% increased HUVEC proliferation rates with enhanced expression of cell cycle proteins[3]
In occlusion/occlusion-like syndromes affecting both periphery and brain (portal hypertension, caval hypertension, intracranial hypertension), BPC-157 simultaneously normalized blood pressure disturbances, healed gastrointestinal and liver lesions, minimized brain lesions and hemorrhage, prevented thrombosis, and preserved neurological function
If side effects persist despite dose and timing adjustments, DSIP may not be the right peptide for your goals
This approach delivers the peptide directly into the joint space, concentrating its effects at the site of cartilage damage, synovial inflammation, or tendon injury within the joint, rather than relying on systemic diffusion from a subcutaneous injection site
Plus, compounded CJC-1295 runs the risk of peptide impurities and harmful immune responses, according to the agency